13,394 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by JW Asset Management LLC

JW Asset Management LLC purchased a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) in the third quarter, Holdings Channel.com reports. The institutional investor purchased 13,394 shares of the company’s stock, valued at approximately $690,000. Eton Pharmaceuticals accounts for about 0.3% of JW Asset Management LLC’s holdings, making the stock its 22nd biggest holding.

Other institutional investors and hedge funds have also bought and sold shares of the company. Toth Financial Advisory Corp grew its position in shares of Eton Pharmaceuticals by 41.7% in the 3rd quarter. Toth Financial Advisory Corp now owns 1,700 shares of the company’s stock worth $88,000 after buying an additional 500 shares during the last quarter. Hilton Head Capital Partners LLC purchased a new position in shares of Eton Pharmaceuticals during the third quarter valued at approximately $26,000. Sterling Capital Management LLC raised its holdings in shares of Eton Pharmaceuticals by 845.7% during the third quarter. Sterling Capital Management LLC now owns 889 shares of the company’s stock valued at $46,000 after acquiring an additional 795 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Eton Pharmaceuticals by 19.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,215 shares of the company’s stock valued at $269,000 after acquiring an additional 855 shares in the last quarter. Finally, SBI Securities Co. Ltd. raised its holdings in shares of Eton Pharmaceuticals by 159.0% during the third quarter. SBI Securities Co. Ltd. now owns 1,852 shares of the company’s stock valued at $95,000 after acquiring an additional 1,137 shares in the last quarter. Hedge funds and other institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Trading Down 10.2%

Shares of NASDAQ ETON opened at $61.45 on Friday. The firm has a 50-day moving average of $55.18 and a 200 day moving average of $37.47. Eton Pharmaceuticals, Inc. has a 1 year low of $14.27 and a 1 year high of $70.64. The stock has a market cap of $1.77 billion, a P/E ratio of 40.70 and a beta of 0.89. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.79 and a quick ratio of 1.58.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.31 by $0.19. The company had revenue of $57.93 million for the quarter, compared to the consensus estimate of $41.98 million. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 104.82%. As a group, sell-side analysts expect that Eton Pharmaceuticals, Inc. will post 1.54 EPS for the current fiscal year.

Insider Transactions at Eton Pharmaceuticals

In other news, Director Paul V. Maier sold 50,000 shares of the company’s stock in a transaction dated Friday, August 28th. The shares were sold at an average price of $59.07, for a total transaction of $2,953,500.00. Following the completion of the sale, the director owned 59,745 shares of the company’s stock, valued at $3,529,137.15. This represents a 45.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Krempa sold 25,000 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $65.07, for a total value of $1,626,750.00. Following the completion of the transaction, the insider directly owned 37,025 shares in the company, valued at approximately $2,409,216.75. This represents a 40.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 82,666 shares of company stock worth $5,045,607 in the last ninety days. Insiders own 16.49% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Weiss Ratings raised Eton Pharmaceuticals from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday. B. Riley Financial boosted their price objective on shares of Eton Pharmaceuticals from $70.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday. HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $70.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, November 6th. Zacks Research cut shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $78.00 target price on shares of Eton Pharmaceuticals in a research report on Thursday, October 15th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $79.75.

About Eton Pharmaceuticals

Eton Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited treatment options. Its work includes bringing new medicines and reformulated or otherwise specialized drug products to market. The company’s products include Alkindi Sprinkle, a hydrocortisone granule formulation used to treat adrenal insufficiency, and Eprontia, an oral solution of topiramate used to treat certain seizure disorders and prevent migraines.